ArticleAmerican journal of obstetrics and gynecology2024
Menopausal vasomotor symptoms and plasma Alzheimer disease biomarkers.
Article in American journal of obstetrics and gynecology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular Biomarkers for Early Detection of Alzheimer's Disease and the Complementary Role of Engineered Nanomaterials: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Report of the FDA's expert panel on hormone therapy.Menopause (New York, N.Y.) · 2026Review
- Evidence of APOE4-related brain vulnerabilities in verbal memory systems in midlife women.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Neuron-Enriched Extracellular Vesicle MicroRNAs Reflect Hormone-Sensitive Neural Pathway Changes from Early to Late Perimenopause.medRxiv : the preprint server for health sciences · 2026Article
- Women's midlife: the front line of Alzheimer prevention.The Journal of clinical investigation · 2026Review
- Blood-based proteomic signatures of spontaneous menopause: Implications for later-life brain aging and Alzheimer's disease risk.Research square · 2026Article
- Blood-based proteomic signatures of spontaneous menopause: Implications for later-life brain aging and Alzheimer's disease risk.medRxiv : the preprint server for health sciences · 2026Article
- Neurologic Complications of Pregnancy and Menopause.Continuum (Minneapolis, Minn.) · 2026Review
- The Effect of Sleep Deprivation on Cognitive Function in Postmenopausal Women: A Systematic Review.International journal of women's health · 2026Review
- Hot flashes: a review.Frontiers in medicine · 2026Review
- Cardiovascular contributions to dementia: Examining sex differences and female-specific factors.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Not your mother's hormone therapy: Highly selective estrogen receptor beta agonists as next-generation therapies for menopausal symptom relief.Hormones and behavior · 2025Review
- Premenopausal bilateral oophorectomy and Alzheimer's disease imaging biomarkers later in life.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Associations between objective sleep metrics and brain structure in cognitively unimpaired adults: interactions with sex and Alzheimer's biomarkers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- One size does not fit all: how type of menopause and hormone therapy matters for brain health.The British journal of psychiatry : the journal of mental science · 2025Review
- Observational
- Article
- Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting.Molecular neurodegeneration · 2024Review
- The novel estrogen receptor beta agonist EGX358 andFrontiers in aging neuroscience · 2024Article
- Rest-activity rhythm characteristics associated with lower cognitive performance and Alzheimer's disease biomarkers in midlife women.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIdentifying risk factors for Alzheimer disease in women is important as women compose two-thirds of individuals with Alzheimer disease. Previous work links vasomotor symptoms, the cardinal menopausal symptom, with poor memory performance and alterations in brain structure, function, and connectivity. These associations are evident when vasomotor symptoms are monitored objectively with ambulatory skin conductance monitors.
objectiveThis study aimed to determine whether vasomotor symptoms are associated with Alzheimer disease biomarkers. STUDY
designBetween 2017 and 2020, the MsBrain study enrolled 274 community-dwelling women aged 45 to 67 years who had a uterus and at least 1 ovary and were late perimenopausal or postmenopausal status. The key exclusion criteria included neurologic disorder, surgical menopause, and recent use of hormonal or nonhormonal vasomotor symptom treatment. Women underwent 24 hours of ambulatory skin conductance monitoring to assess vasomotor symptoms. Plasma concentrations of Alzheimer disease biomarkers, including amyloid β 42-to-amyloid β 40 ratio, phosphorylated tau (181 and 231), glial fibrillary acidic protein, and neurofilament light, were measured using a single-molecule array (Simoa) technology. Associations between vasomotor symptoms and Alzheimer disease biomarkers were assessed via linear regression models adjusted for age, race and ethnicity, education, body mass index, and apolipoprotein E4 status. Additional models adjusted for estradiol and sleep.
resultsA total of 248 (mean age, 59.06 years; 81% White; 99% postmenopausal status) of enrolled MsBrain participants contributed data. Objectively assessed vasomotor symptoms occurring during sleep were associated with significantly lower amyloid β 42/amyloid β 40, (beta, -.0010 [standard error, .0004]; P=.018; multivariable), suggestive of greater brain amyloid β pathology. The findings remained significant after additional adjustments for estradiol and sleep.
conclusionNighttime vasomotor symptoms may be a marker of women at risk of Alzheimer disease. It is yet unknown if these associations are causal.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.